NYSEAMERICAN:MYO Myomo (MYO) Stock Price, News & Analysis $3.75 -0.02 (-0.53%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$3.70▼$3.8750-Day Range N/A52-Week Range$0.85▼$5.64Volume83,454 shsAverage Volume379,142 shsMarket Capitalization$113.36 millionP/E RatioN/ADividend YieldN/APrice Target$7.63 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort Interest Get Myomo alerts: Email Address Myomo MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside103.3% Upside$7.63 Price TargetShort InterestHealthy3.12% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.61Based on 4 Articles This WeekInsider TradingSelling Shares$8,136 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.16) to ($0.02) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.74 out of 5 stars 3.5 Analyst's Opinion Consensus RatingMyomo has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMyomo has only been the subject of 4 research reports in the past 90 days.Read more about Myomo's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.12% of the float of Myomo has been sold short.Short Interest Ratio / Days to CoverMyomo has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Myomo has recently increased by 17.50%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMyomo does not currently pay a dividend.Dividend GrowthMyomo does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MYO. Previous Next 0.8 News and Social Media Coverage News SentimentMyomo has a news sentiment score of -0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Myomo this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for MYO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Myomo insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,136.00 in company stock.Percentage Held by InsidersOnly 4.54% of the stock of Myomo is held by insiders.Percentage Held by Institutions44.99% of the stock of Myomo is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Myomo's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Myomo are expected to grow in the coming year, from ($0.16) to ($0.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Myomo is -13.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Myomo is -13.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMyomo has a P/B Ratio of 11.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsAmerica dodged a crisis — next time it could be much worseLegendary financial forecaster, Dr. Martin Weiss, has been warning us about it for months … He believes the next incident could lead to people seeing their bank accounts frozen.Click here and follow the three simple steps Martin shares in this video to protect your savings whi About Myomo Stock (NYSEAMERICAN:MYO)Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides the MyoPro 2, including control technology, configuration software and user interface, and pop-out battery for extended use of the brace; and MyoPro2+ that comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, the Veterans Administration, and its distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.Read More MYO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MYO Stock News HeadlinesSeptember 7 at 9:18 PM | markets.businessinsider.comDaxor Corporation: A Buy Rating Justified by Strong Performance and Promising Medical Technology OutlookSeptember 6 at 6:31 PM | finance.yahoo.comMedical Exoskeleton Market to grow by USD 2.87 billion from 2024-2028, driven by rising spinal cord injury cases, AI-powered report- TechnavioSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.September 5 at 4:43 PM | finance.yahoo.comMyomo to Participate in Two Investor Conferences in SeptemberAugust 21, 2024 | markets.businessinsider.comMaxim Group Remains a Buy on bioAffinity Technologies, Inc. (BIAF)August 21, 2024 | finance.yahoo.com0M61.SG,0P0001BC6N,0 (0M61.SG)August 19, 2024 | benzinga.comThe Analyst Verdict: Myomo In The Eyes Of 4 ExpertsAugust 19, 2024 | seekingalpha.comMyomo: Intriguing Prospects, But Preferable To Wait For A Further Pullback In The PriceSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Lucid Diagnostics Amidst Growth and Strategic AdvancesAugust 13, 2024 | markets.businessinsider.comAccolade’s Growth and Profitability Outlook Underscored by Buy RatingAugust 9, 2024 | seekingalpha.comMyomo, Inc. (MYO) Q2 2024 Earnings Call TranscriptAugust 8, 2024 | markets.businessinsider.comLake Street Reaffirms Their Buy Rating on Myomo (MYO)August 6, 2024 | businesswire.comMyomo Reports Second Quarter 2024 Financial ResultsJuly 31, 2024 | msn.comCraig-Hallum Initiates Coverage of Myomo (MYO) with Buy RecommendationJuly 26, 2024 | uk.finance.yahoo.comDutch Bros. is gunning for Starbucks' top coffee spotJuly 26, 2024 | msn.comMyomo, Inc. (MYO): Hedge Funds Are Bullish on This Robotics Stock NowJune 5, 2024 | businesswire.comMyomo to Present at the Sidoti Virtual Investor Conference on June 12-13, 2024See More Headlines Receive MYO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Myomo and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Surgical appliances & supplies Sub-IndustryMedical Equipment Current SymbolNYSEAMERICAN:MYO CUSIPN/A CIK1369290 Webmyomo.com Phone(617) 996-9058FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$7.63 High Stock Price Target$8.50 Low Stock Price Target$7.00 Potential Upside/Downside+103.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,150,000.00 Net Margins-44.75% Pretax Margin-43.26% Return on Equity-93.10% Return on Assets-58.72% Debt Debt-to-Equity RatioN/A Current Ratio2.34 Quick Ratio1.94 Sales & Book Value Annual Sales$19.24 million Price / Sales5.89 Cash FlowN/A Price / Cash FlowN/A Book Value$0.32 per share Price / Book11.72Miscellaneous Outstanding Shares30,230,000Free Float27,507,000Market Cap$113.36 million OptionableNot Optionable Beta1.56 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Paul R. Gudonis (Age 69)Chairman, President & CEO Comp: $526.56kMr. David A. Henry (Age 63)Chief Financial Officer Comp: $401.56kDr. Harry Kovelman M.D. (Age 65)Chief Medical Officer Comp: $426.03kColin AndersonGlobal Director of OperationsMr. Joseph ChicoskieDirector of MarketingMs. Galina ShtivelmanSenior Director of Human ResourcesMr. Micah J. Mitchell (Age 48)Chief Commercial Officer Comp: $317.39kMore ExecutivesKey CompetitorsJin Medical InternationalNASDAQ:ZJYLWestaimOTCMKTS:WEDXFTreace Medical ConceptsNASDAQ:TMCINano-X ImagingNASDAQ:NNOXClearPoint NeuroNASDAQ:CLPTView All CompetitorsInsiders & InstitutionsHarry KovelmanSold 2,029 sharesTotal: $8,136.29 ($4.01/share)Herr Investment Group LLCBought 1,200,244 shares on 8/13/2024Ownership: 9.875%Renaissance Technologies LLCSold 146,616 shares on 8/9/2024Ownership: 0.469%AIGH Capital Management LLCBought 115,405 shares on 8/7/2024Ownership: 10.125%Bailard Inc.Bought 33,905 shares on 7/26/2024Ownership: 0.118%View All Insider TransactionsView All Institutional Transactions MYO Stock Analysis - Frequently Asked Questions How have MYO shares performed this year? Myomo's stock was trading at $4.74 at the beginning of 2024. Since then, MYO stock has decreased by 20.9% and is now trading at $3.75. View the best growth stocks for 2024 here. How were Myomo's earnings last quarter? Myomo, Inc. (NYSEAMERICAN:MYO) issued its earnings results on Tuesday, August, 6th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.04. The firm earned $7.52 million during the quarter, compared to analyst estimates of $7.30 million. Myomo had a negative trailing twelve-month return on equity of 93.10% and a negative net margin of 44.75%. Who are Myomo's major shareholders? Myomo's top institutional shareholders include AIGH Capital Management LLC (10.12%), Herr Investment Group LLC (9.88%), Rosalind Advisors Inc. (9.25%) and Renaissance Technologies LLC (0.47%). Insiders that own company stock include Paul R Gudonis, David A Henry, Thomas F Kirk, Harry Kovelman, Milton Mayo Morris, Micah Mitchell and Thomas Aloysius Jr Crowley. View institutional ownership trends. How do I buy shares of Myomo? Shares of MYO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Myomo own? Based on aggregate information from My MarketBeat watchlists, some other companies that Myomo investors own include Genocea Biosciences (GNCA), Agile Therapeutics (AGRX), Sarepta Therapeutics (SRPT), Aclaris Therapeutics (ACRS), Remark (MARK), Synergy Pharmaceuticals (SGYP). This page (NYSEAMERICAN:MYO) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myomo, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myomo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.